NervGen Pharma Grants Stock Options
NervGen Pharma (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company focused on neurorestorative therapeutics, has announced the granting of 545,000 incentive stock options to employees and consultants. The options include:
- 100,000 options to company officers
- 15,000 options to investor relations consultants
- Exercise price set at $2.74 per share
The options are structured in two categories: 15,000 options with a five-year term vesting quarterly over one year, and 530,000 options with a ten-year term vesting semi-annually over two years. All grants comply with TSX Venture Exchange policies and the company's stock option plan.
NervGen Pharma (TSXV: NGEN) (OTCQB: NGENF), un'azienda biotecnologica in fase clinica focalizzata su terapie neurorestorative, ha annunciato l'assegnazione di 545.000 opzioni su azioni incentivanti a dipendenti e consulenti. Le opzioni includono:
- 100.000 opzioni per i dirigenti dell'azienda
- 15.000 opzioni per consulenti delle relazioni con gli investitori
- Prezzo di esercizio fissato a $2,74 per azione
Le opzioni sono strutturate in due categorie: 15.000 opzioni con un termine di cinque anni che maturano trimestralmente per un anno, e 530.000 opzioni con un termine di dieci anni che maturano semestralmente per due anni. Tutti i conferimenti sono conformi alle politiche della Borsa di Toronto Venture e al piano di opzioni su azioni dell'azienda.
NervGen Pharma (TSXV: NGEN) (OTCQB: NGENF), una empresa biotecnológica en etapa clínica centrada en terapias neurorestaurativas, ha anunciado la concesión de 545,000 opciones sobre acciones incentivadas a empleados y consultores. Las opciones incluyen:
- 100,000 opciones para los directivos de la empresa
- 15,000 opciones para consultores de relaciones con inversionistas
- Precio de ejercicio fijado en $2.74 por acción
Las opciones se estructuran en dos categorías: 15,000 opciones con un plazo de cinco años que se consolidan trimestralmente durante un año, y 530,000 opciones con un plazo de diez años que se consolidan semestralmente durante dos años. Todas las concesiones cumplen con las políticas de la Bolsa de Valores de Toronto Venture y con el plan de opciones sobre acciones de la empresa.
NervGen Pharma (TSXV: NGEN) (OTCQB: NGENF)는 신경 회복 치료제에 중점을 둔 임상 단계 생명공학 회사로, 직원 및 컨설턴트에게 545,000개의 인센티브 주식 옵션을 부여한다고 발표했습니다. 옵션에는 다음이 포함됩니다:
- 회사 임원에게 100,000개 옵션
- 투자자 관계 컨설턴트에게 15,000개 옵션
- 주당 행사 가격은 $2.74로 설정됨
옵션은 두 가지 범주로 구성됩니다: 15,000개 옵션은 5년 기간으로 1년 동안 분기별로 발생하고, 530,000개 옵션은 10년 기간으로 2년 동안 반기별로 발생합니다. 모든 부여는 TSX 벤처 거래소 정책 및 회사의 주식 옵션 계획을 준수합니다.
NervGen Pharma (TSXV: NGEN) (OTCQB: NGENF), une entreprise biopharmaceutique en phase clinique axée sur les thérapies neurorestauratives, a annoncé l'octroi de 545 000 options d'achat d'actions incitatives à des employés et consultants. Les options comprennent :
- 100 000 options pour les dirigeants de l'entreprise
- 15 000 options pour les consultants en relations avec les investisseurs
- Prix d'exercice fixé à 2,74 $ par action
Les options sont structurées en deux catégories : 15 000 options avec une durée de cinq ans acquises trimestriellement sur un an, et 530 000 options avec une durée de dix ans acquises semestriellement sur deux ans. Tous les attributions sont conformes aux politiques de la Bourse de Toronto Venture et au plan d'options sur actions de l'entreprise.
NervGen Pharma (TSXV: NGEN) (OTCQB: NGENF), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf neurorestaurative Therapeutika konzentriert, hat die Gewährung von 545.000 Anreizaktienoptionen an Mitarbeiter und Berater bekannt gegeben. Die Optionen umfassen:
- 100.000 Optionen für Unternehmensleiter
- 15.000 Optionen für Berater der Investorenbeziehungen
- Ausübungspreis von $2,74 pro Aktie
Die Optionen sind in zwei Kategorien strukturiert: 15.000 Optionen mit einer Laufzeit von fünf Jahren, die vierteljährlich über ein Jahr fällig werden, und 530.000 Optionen mit einer Laufzeit von zehn Jahren, die halbjährlich über zwei Jahre fällig werden. Alle Zuwendungen entsprechen den Richtlinien der TSX Venture Exchange und dem Aktienoptionsplan des Unternehmens.
- None.
- None.
Vancouver, British Columbia--(Newsfile Corp. - March 14, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that it has granted 545,000 incentive stock options (the "Options") to employees and consultants of the company, including 100,000 to the company's officers and 15,000 to consultants providing investor relations services. The Options are exercisable at a price of
About NervGen
NervGen (TSXV: NGEN) (OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company is testing the clinical efficacy of its lead molecule, NVG-291, in a Phase 1b/2a clinical trial in spinal cord injury and has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. For more information, visit www.nervgen.com and follow NervGen on X, LinkedIn, and Facebook for the latest news on the company.
Contacts
Huitt Tracey, Investor Relations
htracey@nervgen.com
604.537.2094
Bill Adams, Chief Financial Officer
info@nervgen.com
778.731.1711
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/244720
FAQ
What is the exercise price of NervGen Pharma's (NGENF) newly granted stock options?
How many stock options did NervGen Pharma (NGENF) grant to its officers in March 2025?
What is the vesting schedule for NGENF's March 2025 stock option grant?
How long are the exercise periods for NervGen Pharma's (NGENF) March 2025 stock options?
